Prestige Consumer Q4 2024 Adj EPS $1.02 Misses $1.14 Estimate, Sales $277.00M Miss $287.47M Estimate
Portfolio Pulse from Benzinga Newsdesk
Prestige Consumer Healthcare reported its Q4 2024 adjusted EPS at $1.02, missing the $1.14 estimate, and sales at $277.00M, below the $287.47M estimate. This represents a 3.10% decrease in sales compared to the same period last year.
May 14, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Prestige Consumer Healthcare's Q4 2024 earnings and sales missed analyst estimates, with a year-on-year sales decrease of 3.10%.
Missing both EPS and sales estimates, especially when coupled with a year-on-year decrease in sales, is typically viewed negatively by the market. This could lead to a short-term decrease in PBH's stock price as investors adjust their expectations based on the company's reported performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100